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The airways in CF are characterised by a reduction in the water content of the
airway surface liquid (ASL) and accumulation of thick mucus that is a precursor for
chronic infection, inﬂammation and tissue damage. Inhaled mannitol is an osmotic
agent that increases the water content of the ASL, improves mucociliary clearance
and in studies has shown to improve lung function, lung hygiene and be well
tolerated [1,2]. This phase III study was designed to assess the efﬁcacy and safety
of inhaled mannitol over the longer term.
Methods: The study was a randomised, double-blind, parallel, placebo-controlled
design, where subjects inhaled 400mg mannitol or control, twice daily for 6 months,
with a further option of participating in a 6−12 month open label phase. Patients
had conﬁrmed CF, were >6 yrs with an FEV1 30 and <90% predicted, and were
not using hypertonic saline.
Demographics: Preliminary baseline data were available for the 295 eligible
patients. Patients were aged 6−56 yrs (mean 22 yrs) with 44.5% female and mean
BMI of 21.33 kg/m2. The baseline % predicted FEV1 was 62.0±16.44% and 55%
of the patients were taking rhDNase.
Objectives: The primary endpoint was change in FEV1. The study was also powered
to assess the change in FEV1 in the group of patients taking rhDNase. Secondary
endpoints included pulmonary exacerbations, quality of life, and antibiotic treat-
ment.
Results: The 6 month blinded study completed in March 2009. This will be the
ﬁrst presentation of the CF-301 study results.
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Neutrophilic inﬂammation in CF is associated with excessive Neutrophil Elas-
tase (NE) levels, which cause further damage to the respiratory tissue. The major
antagonist of NE is AAT. In CF, the unregulated inﬂammatory process overwhelms
the normal NE/AAT balance, leading to accumulation of NE in the lung and
ultimately to tissue damage. The rational for inhaled AAT therapy is to treat
this imbalance and prevent further damage to the lung tissue by reducing the
severity of this destructive cycle. Recently, a high purity, liquid, ready-to-use AAT
was developed (Kamada Ltd., Israel) for inhalation using the eFlow® electronic
nebulizer (PARI Pharma, Germany). The aim of this phase II study was to assess
the safety and efﬁcacy of inhaled AAT in CF patients.
Study design: Double-blind, randomized, placebo-controlled, repeated dose. Study
method: 21 patients were randomized (2:1) to receive inhaled 80mg active AAT
or placebo once a day. The study comprised three treatment periods, 1 day, 7 days
and 28 days. Safety and efﬁcacy variables were tested.
Results: All patients completed the study without SAEs. One patient reported
mouth dryness probably related to the study drug. A decrease in the absolute sputum
neutrophil counts and in sputum NE levels was observed in the AAT group, but
not in the placebo group.
Conclusion: Kamada AAT is safe and well tolerated when inhaled daily for
28 days. The reduction of neutrophils and NE detected in sputum suggests an anti-
inﬂammatory effect in CF patients. Further clinical trials are warranted to evaluate
the effects of inhaled AAT on disease progression.
Supported by: Kamada Ltd. Israel.
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This randomized, double-blind, placebo-controlled study evaluated the safety, tol-
erability, pharmacokinetics, and efﬁcacy of VX-770, a CFTR potentiator, in adults
with CF and at least one G551D-CFTR allele. Part 1 was a cross-over design in
which subjects were randomized to receive placebo (n = 4) or VX-770 q12 h at either
25 and 75mg (n = 8) or 75 and 150mg (n = 8) doses in two 14-day periods separated
by a washout. Part 2 included distinct subjects from Part 1 randomized to placebo
(n = 4), 150mg VX-770 (n = 8), or 250mg VX-770 (n = 7) q12 h for 28 days. Most
subjects (82%) were G551D/F508del-CFTR compound heterozygotes. VX-770 was
generally well-tolerated at all doses and no subject withdrew from treatment. Most
adverse events were mild or moderate in severity and no drug-related serious adverse
events were reported. Within-subject comparisons showed statistically signiﬁcant
changes from baseline at Day 14 (Parts 1 and 2) and Day 28 (Part 2) for FEV1,
sweat chloride, and nasal potential difference (NPD) zero chloride plus isoproterenol
response in the VX-770 75, 150, and 250mg dose groups. At Day 28 in subjects
in the VX-770 150mg dose group, the median relative change from baseline in
FEV1%pred was +8.7% (range 2.2, 31.3; p< 0.01), and absolute change from
baseline in sweat chloride was −59mmol/L (−66, −19; p< 0.02) and NPD was
−3.5mV (−8.2, 0.5; p< 0.02). These results suggest that further evaluation of VX-
770 is warranted.
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One of the major therapeutic strategy in Cystic Fibrosis (CF) aims to develop mod-
ulators of CFTR (CF Transmembrane conductance Regulator) channels. Previously,
we identiﬁed a new family of water-soluble and non-toxic CFTR inhibitors: the
methylglyoxal-alpha-aminoazaheterocycle adducts (Routaboul et al; JPET 2007).
Interestingly, in a structure-activity relationship study, some of them, like GPact-
11a, were found positive as CFTR potentiator.
Firstly, using in vitro, ex vivo and in vivo techniques we demonstrated that GPact-
11a is an activator of wt-CFTR (EC50 = 5mM). Indeed GPact-11a potentiates the
forskolin-induced iodide efﬂux. Furthermore, by recording short-circuit current, we
found that GPact-11a induced a CFTRinh-172 inhibited chloride secretion in cftr
+/+
mice. Then, in vivo, we observed an increase of the salivary secretion in the presence
of GPact-11a in cftr+/+ mice, but not in cftr−/− mice. Using the potential-sensitive
probe oxonol, the effect of GPact-11a on F508del-CFTR rescued by miglustat was
assessed by single-cell ﬂuorescence imaging. We demonstrated that GPact-11a not
only potentiates the forskolin induced response but more importantly activates alone
the rescued F508del-CFTR.
To conclude, this work identiﬁes, using in vitro, ex vivo and in vivo experiments,
a novel activator of CFTR: GPact-11a. This agent, non-toxic and water-soluble,
represents a good candidate, alone or in combination with a F508del-CFTR
corrector, for the development of a pharmacologic therapy in CF.
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